Celyad Oncology Stock Down 15.2 %
Shares of CYAD opened at $1.84 on Thursday. Celyad Oncology has a twelve month low of $1.51 and a twelve month high of $5.32. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average price is $1.86 and its 200-day moving average price is $2.31.
About Celyad Oncology
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.